https://nexcella.com/blog/ https://nexcella.com/2024/07/26/california-institute-for-regenerative-medicine-awards-funding-for-car-t-nxc-201-u-s-al-amyloidosis-clinical-trial-nexicart-2/ 2024-07-26T01:38:25+00:00 https://nexcella.com/2024/04/18/nexcella-an-immix-biopharma-subsidiary-on-track-to-dose-nxc-201-patients-in-united-states/ 2024-04-18T13:38:58+00:00 https://nexcella.com/2024/01/04/nexcella-announces-dr-vaishali-sanchorawala-al-amyloidosis-thought-leader-director-of-the-amyloidosis-center-at-boston-university-and-boston-medical-center-joins-scientific-advisory-board/ 2024-01-04T14:48:20+00:00 https://nexcella.com/2023/12/18/nexcella-announces-dr-marko-radic-autoimmune-car-t-pioneer-and-associate-professor-at-the-university-of-tennessee-health-science-center-joins-scientific-advisory-board/ 2023-12-18T14:48:33+00:00 https://nexcella.com/2023/12/11/nexcella-announces-100-overall-response-rate-n10-23-7-months-best-response-duration-ongoing-for-car-t-nxc-201-in-relapsed-refractory-al-amyloidosis-patients-at-ash-2023/ 2023-12-11T14:48:10+00:00 https://nexcella.com/2023/11/21/nexcella-announces-fda-approval-of-ind-application-for-car-t-nxc-201-enabling-u-s-patient-dosing/ 2023-11-21T14:58:34+00:00 https://nexcella.com/2023/11/06/nexcella-presents-nxc-201-data-at-65th-american-society-of-hematology-ash-annual-meeting-in-9-relapsed-refractory-al-amyloidosis-patients/ 2023-11-06T14:19:08+00:00 https://nexcella.com/2023/11/06/nexcella-presents-nxc-201-data-at-65th-american-society-of-hematology-ash-annual-meeting-in-63-relapsed-refractory-multiple-myeloma-patients/ 2023-11-06T13:46:52+00:00 https://nexcella.com/2023/10/26/nexcella-announces-dr-michaela-liedtke-stanford-medicine-cancer-center-hematology-program-lead-and-co-director-stanford-amyloid-center-joins-scientific-advisory-board/ 2023-10-26T13:03:32+00:00 https://nexcella.com/2023/10/16/nexcella-completes-3rd-nxc-201-engineering-batch-at-its-u-s-car-t-manufacturing-site/ 2023-10-16T13:12:03+00:00 https://nexcella.com/2023/10/03/nexcella-announces-complete-response-in-9th-relapsed-refractory-al-amyloidosis-patient-in-nxc-201-clinical-trial-at-ims-20th-annual-meeting/ 2023-10-03T13:20:16+00:00 https://nexcella.com/2023/10/02/nexcella-announces-72-patient-nxc-201-clinical-data-at-the-ims-20th-annual-meeting-95-overall-response-rate-in-multiple-myeloma/ 2023-10-02T12:11:47+00:00 https://nexcella.com/2023/09/21/u-s-food-and-drug-administration-approves-orphan-drug-designation-for-nexcella-nxc-201-as-a-treatment-for-amyloid-light-chain-al-amyloidosis/ 2023-09-21T13:05:54+00:00 https://nexcella.com/2023/09/19/nexcella-completes-2nd-nxc-201-engineering-batch-at-its-u-s-car-t-manufacturing-site/ 2023-09-19T13:16:20+00:00 https://nexcella.com/2023/09/07/nexcella-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference/ 2023-09-07T12:48:43+00:00 https://nexcella.com/2023/09/01/nexcella-announces-dr-suzanne-lentzsch-director-of-the-multiple-myeloma-and-amyloidosis-program-at-the-college-of-physicians-and-surgeons-of-columbia-university-and-at-new-york-presbyterian-hospital/ 2023-09-01T12:46:05+00:00 https://nexcella.com/2023/08/23/u-s-food-and-drug-administration-approves-orphan-drug-designation-for-nxc-201-as-a-treatment-for-multiple-myeloma/ 2023-08-23T12:43:41+00:00 https://nexcella.com/2023/08/18/nexcella-announces-dr-heather-landau-memorial-sloan-kettering-cancer-center-amyloidosis-program-director-joins-nexcella-scientific-advisory-board/ 2023-08-18T13:25:35+00:00 https://nexcella.com/2023/08/16/nexcella-announces-additional-nxc-201-al-amyloidosis-clinical-data-accepted-for-oral-presentation-at-the-20th-international-myeloma-society-annual-meeting-september-27-30-athens-greece/ 2023-08-16T13:11:51+00:00 https://nexcella.com/2023/07/25/nexcella-announces-nxc-201-multiple-myeloma-clinical-data-abstract-accepted-for-presentation-at-the-20th-international-myeloma-society-annual-meeting/ 2023-07-25T12:49:09+00:00 https://nexcella.com/2023/07/10/nexcella-completes-initial-nxc-201-engineering-batch-at-its-u-s-car-t-manufacturing-site/ 2023-07-10T13:54:23+00:00 https://nexcella.com/2023/06/26/nexcella-completes-pre-ind-meeting-with-fda-on-nxc-201-us-clinical-trial/ 2023-06-26T13:56:33+00:00 https://nexcella.com/2023/06/22/nexcella-appoints-edward-j-borkowski-former-chief-financial-officer-of-mylan-n-v-to-board-of-directors/ 2023-06-22T14:00:45+00:00 https://nexcella.com/2023/06/20/nexcella-appoints-jeffrey-h-cooper-former-chief-financial-officer-of-biomarin-to-board-of-directors/ 2023-06-20T13:50:20+00:00 https://nexcella.com/2023/06/16/nexcella-appoints-mary-sue-coleman-former-johnson-johnson-independent-director-to-board-of-directors/ 2023-06-16T13:50:04+00:00 https://nexcella.com/2023/06/12/nexcella-appoints-henry-mckinnell-jr-former-chairman-ceo-of-pfizer-inc-to-board-of-directors/ 2023-06-12T13:56:48+00:00 https://nexcella.com/2023/05/26/nexcella-announces-commencement-of-nxc-201-engineering-batches-at-its-u-s-car-t-manufacturing-site/ 2023-05-26T14:00:29+00:00 https://nexcella.com/2023/05/21/nexcella-announces-positive-nxc-201-clinical-results-at-asgct-100-overall-response-rate-in-darzalex-relapsed-refractory-al-amyloidosis-with-zero-icans-in-ongoing-nexicart-1-phase-1b-2a-clinical-trial/ 2023-05-21T20:05:43+00:00 https://nexcella.com/2023/05/04/nexcella-announces-late-breaking-nxc-201-clinical-data-abstract-accepted-for-oral-presentation-at-the-26th-annual-meeting-of-the-american-society-of-gene-and-cell-therapy-asgct/ 2023-05-04T16:36:07+00:00 https://nexcella.com/2023/04/26/nexcella-announces-positive-58-patient-nxc-201-clinical-data-100-overall-response-rate-in-light-chain-al-amyloidosis-92-overall-response-rate-in-multiple-myeloma-at-the-ebmt-49th-annual-meeting-i/ 2023-04-26T21:36:32+00:00 https://nexcella.com/2023/04/04/nexcella-announces-poster-presentation-at-the-european-society-for-blood-and-marrow-transplantation-49th-annual-meeting/ 2023-04-04T12:06:11+00:00 https://nexcella.com/2023/03/31/nexcella-announces-2023-haematologica-editorial-highlighting-nxc-201-efficacy-in-the-context-of-u-s-food-and-drug-administration-approved-bcma-car-t-cells/ 2023-03-31T12:05:42+00:00 https://nexcella.com/2023/03/30/nexcella-announces-new-positive-nxc-201-clinical-data-demonstrating-100-complete-responses-in-al-amyloidosis-patients-additional-positive-multiple-myeloma-safety-data-demonstrating-nxc-201-outpatien/ 2023-03-30T20:21:53+00:00 https://nexcella.com/2023/03/06/nexcella-to-discuss-recent-positive-nxc-201-clinical-data-in-al-amyloidosis-and-multiple-myeloma-at-the-35th-annual-roth-conference-on-march-14/ 2023-03-06T13:05:57+00:00 https://nexcella.com/2023/02/27/nexcella-announces-50-patients-already-treated-with-car-t-nxc-201-estimates-100-patient-total-enrollment-for-u-s-food-and-drug-administration-approval-bla-submission/ 2023-02-27T13:50:57+00:00 https://nexcella.com/2023/02/15/nexcella-enters-into-u-s-gmp-manufacturing-agreement-to-expand-ongoing-nxc-201-phase-1b-2-clinical-trial-to-the-u-s/ 2023-02-17T15:54:32+00:00 https://nexcella.com/2023/02/09/nexcella-inc-presents-42-patient-interim-data-with-90-overall-response-rate-in-relapsed-or-refractory-multiple-myeloma-at-nxc-201-therapeutic-dose-from-its-phase-1-expansion-trial-at-the-5th-europe/ 2023-02-12T18:46:17+00:00 https://nexcella.com/2022/12/14/nexcella-inc-in-licenses-nxc-201-bcma-targeted-next-generation-car-t-therapy-demonstrating-high-complete-response-rate-in-heavily-pre-treated-multiple-myeloma-71-complete-responses-and-al-amyloid/ 2023-02-12T18:45:53+00:00 https://nexcella.com/2022/12/28/nexcella-inc-announces-poster-presentation-at-the-european-society-for-blood-and-marrow-transplantation-and-european-hematology-association-5th-annual-european-car-t-cell-meeting/ 2023-01-06T13:08:49+00:00 https://nexcella.com/2023/01/06/nexcella-inc-announces-additional-positive-nxc-201-clinical-data-demonstrating-100-complete-responses-in-relapsed-refractory-al-amyloidosis-patients-duration-of-response-not-yet-reached/ 2023-01-06T13:08:03+00:00